来自NEOLEV1和NEOLEV2研究的药理动力学和药理动力学数据
Cynthia Sharpe1,2, Derek Z Yang3, Richard H Haas2,4
1Paediatric Neurology, Starship Children's Health, Auckland, New Zealand CynthiaS@adhb.govt.nz.
Archives of disease in childhood
|June 20, 2024
概括
在高剂量的新生儿中, levetiracetam (LEV) 显示出可预测的药理动力学. 这项研究支持进一步调查新生儿发作的非常高剂量LEV.
科学领域:
- 新生儿神经病学 新生儿神经病学
- 药理动力学 药理动力学
- 临床药理学 临床药理学
背景情况:
- 新生儿发作是一个重大的临床挑战.
- 列维 (Lev) 是一种抗药物,在新生儿中具有潜在的效用.
- 之前的研究已经在新生儿群体中探索了LEV,需要进一步的药理动力学和药理动力学评估.
研究的目的:
- 为了确认 levetiracetam (LEV) 在新生儿中高剂量的可预测的药理动力学 (PK).
- 调查LEV的药理动力学 (PD),包括其对病负担的影响.
- 在这个人群中建立LEV的种群药理动力学 (PopPK) 模型.
主要方法:
- 使用非线性混合效应建模的NEOLEV1和NEOLEV2试验的药理动力学数据的分析.
- 使用连续电脑电图 (cEEG) 对 levetiracetam 对负担的影响的后期分析.
- 确定清除率 (CL) 和分布量 (Vd),并确定显著的共变量.
主要成果:
- 列维 (LEV) 显示出可预测的药理动力学 (PK),估计CL为0.0538 L/小时,Vd为0.832 L.
- 在产后年龄和LEV清除之间观察到正相关性.
- 在服用LEV后30分钟内,人们注意到发作负担的减少,28%的人实现了发作自由,25%的人经历了50%的减少.
结论:
- 莱维他 (LEV) 显示出可预测的药理动力学,即使在新生儿中服用更高剂量.
- 已建立的PopPK模型为该人群的LEV剂量提供了一个强大的框架.
- 这些发现支持研究新生儿非常高剂量LEV治疗方案的潜力.
相关概念视频
Analysis of Population Pharmacokinetic Data
252
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
252
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
120
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
120
Nonlinear Pharmacokinetics: Overview
352
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
352
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
57
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
57
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
156
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
156


